Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 1931 Neoplasms 1385 Carcinoma, Non-Small-Cell Lung 1324 Prostatic Neoplasms 1070 Multiple Myeloma 855 Leukemia, Myeloid, Acute 759 Neoplasm Metastasis 691 Colorectal Neoplasms 676 Melanoma 666 Lung Neoplasms 665 Lymphoma 655 Leukemia 591 Lymphoma, Non-Hodgkin 587 Leukemia, Lymphocytic, Chronic, B-Cell 529 Ovarian Neoplasms 517 Pancreatic Neoplasms 493 Precursor Cell Lymphoblastic Leukemia-Lymphoma 471 Recurrence 466 Myelodysplastic Syndromes 421 Lymphoma, Follicular 407 Head and Neck Neoplasms 401 Glioblastoma 376 Carcinoma, Renal Cell 375 Lymphoma, Large B-Cell, Diffuse 372 Brain Neoplasms 370 Hodgkin Disease 352 Carcinoma, Hepatocellular 324 Squamous Cell Carcinoma of Head and Neck 323 Lymphoma, Mantle-Cell 302 Sarcoma 281

Interventions

talazoparib 1 enzalutamide 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Has results × mCRPC × Clear all

NCT03395197 2026-04-22

TALAPRO-2

Pfizer

Phase 3 Active not recruiting

1,054 enrolled 21 charts 1 FDA

mCRPC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡